GSK 将来の成長

Future 基準チェック /46

GSK利益と収益がそれぞれ年間22.4%と3.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に28.7% 22.1%なると予測されています。

主要情報

22.4%

収益成長率

22.1%

EPS成長率

Pharmaceuticals 収益成長	18.5%
収益成長率	3.9%
将来の株主資本利益率	28.7%
アナリストカバレッジ	Good
最終更新日	13 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:GS71 - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	34,338	6,487	6,489	9,537	16
12/31/2025	32,451	5,802	5,615	8,483	17
12/31/2024	31,271	3,544	3,962	6,617	17
9/30/2024	31,311	2,511	4,917	7,421	N/A
6/30/2024	31,446	4,033	5,222	7,479	N/A
3/31/2024	30,740	4,484	5,330	7,673	N/A
12/31/2023	30,328	4,928	4,436	6,768	N/A
9/30/2023	29,652	6,078	3,247	5,477	N/A
6/30/2023	29,334	5,373	2,486	4,586	N/A
3/31/2023	29,085	4,455	2,892	4,914	N/A
12/31/2022	29,324	4,461	5,341	7,403	N/A
9/30/2022	29,024	3,387	7,620	9,265	N/A
6/30/2022	27,822	3,505	8,073	10,506	N/A
3/31/2022	26,731	4,013	7,611	10,163	N/A
12/31/2021	24,696	3,316	5,939	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	24,354	4,873	6,839	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	N/A	6,991	N/A
3/31/2018	30,024	1,035	N/A	6,637	N/A
12/31/2017	30,186	1,532	N/A	6,918	N/A
9/30/2017	30,133	2,335	N/A	7,040	N/A
6/30/2017	29,832	1,931	N/A	6,910	N/A
3/31/2017	29,044	1,676	N/A	7,138	N/A
12/31/2016	27,889	912	N/A	6,497	N/A
9/30/2016	26,589	301	N/A	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A
12/31/2015	23,923	8,422	N/A	2,569	N/A
9/30/2015	23,823	9,809	N/A	3,278	N/A
6/30/2015	23,342	9,672	N/A	4,070	N/A
3/31/2015	23,015	10,177	N/A	4,619	N/A
12/31/2014	23,006	2,756	N/A	5,176	N/A
9/30/2014	23,726	4,184	N/A	5,153	N/A
6/30/2014	24,590	4,752	N/A	5,957	N/A
3/31/2014	25,647	5,143	N/A	6,902	N/A
12/31/2013	26,505	5,436	N/A	7,222	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GS71の予測収益成長率 (年間22.4% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: GS71の収益 ( 22.4% ) はGerman市場 ( 20.7% ) よりも速いペースで成長すると予測されています。

高成長収益: GS71の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: GS71の収益 ( 3.9% ) German市場 ( 5.6% ) よりも低い成長が予測されています。

高い収益成長: GS71の収益 ( 3.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GS71の自己資本利益率は、3年後には高くなると予測されています ( 28.7 %)

GSK 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: UK£0.014 loss per share (vs UK£0.36 profit in 3Q 2023)

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings released: EPS: UK£0.29 (vs UK£0.40 in 2Q 2023)

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings released: EPS: UK£0.26 (vs UK£0.37 in 1Q 2023)

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: UK£1.22 (vs UK£1.11 in FY 2022)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘